During the last session, United Therapeutics Corp (NASDAQ:UTHR)’s traded shares were 0.89 million, with the beta value of the company hitting 0.58. At the end of the trading day, the stock’s price was $318.85, reflecting an intraday loss of -0.47% or -$1.52. The 52-week high for the UTHR share is $417.82, that puts it down -31.04 from that peak though still a striking 16.27% gain since the share price plummeted to a 52-week low of $266.98. The company’s market capitalization is $14.38B, and the average trade volume was 476.87K shares over the past three months.
United Therapeutics Corp (UTHR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.80. UTHR has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 7.06.
United Therapeutics Corp (NASDAQ:UTHR) trade information
United Therapeutics Corp (UTHR) registered a -0.47% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.47% in intraday trading to $318.85, hitting a weekly high. The stock’s 5-day price performance is 3.28%, and it has moved by 5.20% in 30 days. Based on these gigs, the overall price performance for the year is 18.47%.
The consensus price target of analysts on Wall Street is $314, which implies a decrease of -1.54% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $314 and $314 respectively. As a result, UTHR is trading at a premium of 1.52% off the target high and 1.52% off the low.
United Therapeutics Corp (UTHR) estimates and forecasts
In the rating firms’ projections, revenue will increase 11.85% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 802.34M as predicted by 10 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to 834.73M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 714.9M and 748.9M respectively. In this case, analysts expect current quarter sales to grow by 12.23% and then jump by 11.46% in the coming quarter.
While earnings are projected to return 13.05% in 2025, the next five years will return 6.49% per annum.
UTHR Dividends
United Therapeutics Corp is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 4.42 million shares, is of VANGUARD GROUP INC’s that is approximately 9.9526% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.41 billion.
Also, the Mutual Funds coming in first place with the largest holdings of United Therapeutics Corp (UTHR) shares are iShares Trust-iShares Core S&P Mid-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Apr 30, 2025 indicates that iShares Trust-iShares Core S&P Mid-Cap ETF owns about 1.45 shares. This amounts to just over 3.20 percent of the company’s overall shares, with a $460.9 million market value. The same data shows that the other fund manager holds slightly less at 1.41, or about 3.14% of the stock, which is worth about $451.13 million.
